

Crysvita® (burosumab-twza) – Expanded indication

- On September 30, 2019, <u>Ultragenyx and Kyowa Kirin announced</u> the FDA approval of <u>Crysvita</u> (<u>burosumab-twza</u>), for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
 - Crysvita was previously approved for this indication in adult and pediatric patients 1 year of age and older.
- The safety and effectiveness of Crysvita in patients 6 months to 1 year and adolescents are supported by evidence from the studies in pediatric patients 1 year to less than 13 years of age with additional modeling and simulation of adult and pediatric pharmacokinetic and pharmacodynamic data to inform dosing.
- The recommended starting dose of Crysvita in pediatric patients who weigh less than 10 kg is 1 mg/kg of body weight rounded to the nearest 1 mg, administered subcutaneously every two weeks. For patients who weigh more than 10 kg, the starting dose regimen is 0.8 mg/kg of body weight rounded to the nearest 10 mg, administered every two weeks. The minimum starting dose is 10 mg up to a maximum dose of 90 mg.
 - The dose may be increased up to approximately 2 mg/kg (maximum 90 mg) administered every two weeks to achieve normal serum phosphorus.
 - Refer to the Crysvita drug label for additional dosing and administration recommendations.



optumrx.com

 $OptumRx^{@}\ specializes\ in\ the\ delivery,\ clinical\ management\ and\ affordability\ of\ prescription\ medications\ and\ consumer\ health\ products.$ We are an $Optum^{@}\ company\ --$ a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.